Daidzein and puerarin synergistically suppress gastric cancer proliferation via STAT3/FAK pathway Inhibition.

Abstract

Background: Gastric cancer (GC) is the world's health is seriously threatened by a prevalent form of aggressive tumor with a dismal prognosis. The occurrence of gastric cancer poses a concern for public health since it is a malignant tumor with an enhanced incidence and fatality level.

Objective: The purpose of this study was to determine if the natural drug Daidzein (DZN) and Puerarin (PRN) together effectively suppress the proliferation of GC cells by blocking the STAT3/FAK intervention signalling pathways in BGC-823 cells.

Materials and methods: Following a 24-hour treatment with the combination of DZN and PRN, the cells were examined for a number of assays. The MTT test was used to investigate the cytotoxicity of the DZN + PNR combination. Acridine orange/ethidium bromide (AO/EtBr) dual staining experiments were utilized to investigate apoptotic alterations, and Western blotting and flow cytometry were used to assess the protein expressions of the cell survival, cell cycle, proliferation, and apoptosis proteins.

Results: Our findings showed that, DZN and PRN possessed anticancer properties by blocking the STAT3/FAK signaling cascade. Moreover, we discovered that the DZN and PRN combo reduced the protein levels of STAT3-FAK-dependent targeted genes, such as cyclin-D1, Bcl-2, Bax, MMP-2, prevented the phosphorylation and activation of STAT3, FAK.

Conclusion: The current study's findings suggest that the simultaneous administration of DZN and PNR can stop gastric cancer cells from proliferating, trigger apoptosis, and disrupt their cell cycle.